184 related articles for article (PubMed ID: 36815259)
1. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
Salem JE; Bretagne M; Abbar B; Leonard-Louis S; Ederhy S; Redheuil A; Boussouar S; Nguyen LS; Procureur A; Stein F; Fenioux C; Devos P; Gougis P; Dres M; Demoule A; Psimaras D; Lenglet T; Maisonobe T; De Chambrun MP; Hekimian G; Straus C; Gonzalez-Bermejo J; Klatzmann D; Rigolet A; Guillaume-Jugnot P; Champtiaux N; Benveniste O; Weiss N; Saheb S; Rouvier P; Plu I; Gandjbakhch E; Kerneis M; Hammoudi N; Zahr N; Llontop C; Morelot-Panzini C; Lehmann L; Qin J; Moslehi JJ; Rosenzwajg M; Similowski T; Allenbach Y
Cancer Discov; 2023 May; 13(5):1100-1115. PubMed ID: 36815259
[TBL] [Abstract][Full Text] [Related]
2. Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors.
Dougan M
Cancer Discov; 2023 May; 13(5):1040-1042. PubMed ID: 37139724
[TBL] [Abstract][Full Text] [Related]
3. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
Nguyen LS; Bretagne M; Arrondeau J; Zahr N; Ederhy S; Abbar B; Pinna B; Allenbach Y; Mira JP; Moslehi J; Rosenzwajg M; Salem JE
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383117
[TBL] [Abstract][Full Text] [Related]
4. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
6. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Wei SC; Meijers WC; Axelrod ML; Anang NAS; Screever EM; Wescott EC; Johnson DB; Whitley E; Lehmann L; Courand PY; Mancuso JJ; Himmel LE; Lebrun-Vignes B; Wleklinski MJ; Knollmann BC; Srinivasan J; Li Y; Atolagbe OT; Rao X; Zhao Y; Wang J; Ehrlich LIR; Sharma P; Salem JE; Balko JM; Moslehi JJ; Allison JP
Cancer Discov; 2021 Mar; 11(3):614-625. PubMed ID: 33257470
[TBL] [Abstract][Full Text] [Related]
7. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
[No Abstract] [Full Text] [Related]
8. Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome.
Byer SH; Stewart C; Mansour S; Grewal US
Eur J Cancer; 2024 May; 202():114027. PubMed ID: 38507971
[No Abstract] [Full Text] [Related]
9. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Jespersen MS; Fanø S; Stenør C; Møller AK
Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
[TBL] [Abstract][Full Text] [Related]
10. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
11. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
13. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
14.
Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
[TBL] [Abstract][Full Text] [Related]
15. Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti-PD-1 Immune Checkpoint Inhibitor Cancer Therapy.
Racine JJ; Bachman JF; Zhang JG; Misherghi A; Khadour R; Kaisar S; Bedard O; Jenkins C; Abbott A; Forte E; Rainer P; Rosenthal N; Sattler S; Serreze DV
J Immunol; 2024 Apr; 212(8):1287-1306. PubMed ID: 38426910
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
Matzen E; Bartels LE; Løgstrup B; Horskær S; Stilling C; Donskov F
Cardiooncology; 2021 Aug; 7(1):27. PubMed ID: 34365980
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
20. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
